Vitamin K and Cognition in Coronary Heart Disease (NutriCog)

What this study is about

The purpose of this pilot study is to obtain a preliminary assessment of the effect of VK supplementation on cognitive performance and vascular function in adults with stable Coronary Heart Disease (CHD)

Who can join (things the study team will check)

✅ You may be able to join if…

• Men and women
• Age 60 years and older
• Medically documented stable Coronary Heart Disease (CHD)
• Daily dietary intakes of phylloquinone <150 mcg
• Non-consumption of vitamin K supplements (i.e. K1 or K2, singly or in combination with other nutrients), or other cognitive aids
• Good French or English understanding
• Physical exercise not exceeding 2.5 hours/week of moderate to vigorous aerobic activity
• Capacity and willingness to sign informed consent

🚫 You may not be able to join if…

• Recent acute coronary syndrome (<3 months) or recent coronary revascularization (bypass surgery or percutaneous coronary intervention, <3 months)
• Known left ventricular dysfunction (LVEF < 40%) or chronic heart failure
• Recent modification of medication (<2 weeks)
• Warfarin (Coumadin) use
• Cognitive impairment (based on telephone version of the Mini-Mental State Examination test, score <19/23)
• Diagnosis of depression or uncontrolled anxiety
• Malabsorption disorder (advanced liver disease, Crohn's disease)
• Patient with auditory or vision impairments not properly corrected by glasses or hearing aids
• Unable to read the informed consent form or unable to understand the oral explanations provided by the assessor

Where this trial is running

• Montreal Heart Institute, Montreal, Quebec, Canada

Who to contact

Guylaine Ferland, PhD · +1 (514) 376-3330 · guylaine.ferland@umontreal.ca

It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT06855953.